{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:30:07Z","timestamp":1785529807920,"version":"3.56.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013806","name":"Shenyang Pharmaceutical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013806","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bcp.2026.118200","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T23:45:57Z","timestamp":1782431157000},"page":"118200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"P2","title":["Dapagliflozin ameliorates diabetic kidney disease by inhibiting oxidative stress and AIM2-dependent pyroptosis via SIRT1 activation"],"prefix":"10.1016","volume":"251","author":[{"given":"Hao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunliu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bihan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2026.118200_b0005","doi-asserted-by":"crossref","unstructured":"E. M\u0142ynarska, D. Bu\u0142awska, W. Czarnik, J. Hajdys, G. Majchrowicz, F. Prusinowski, M. Stabrawa, J. Rysz, B. Franczyk, Novel insights into diabetic kidney disease, Int. J. Mol. Sci. 25(18) (2024). http:\/\/doi.org\/10.3390\/ijms251810222.","DOI":"10.3390\/ijms251810222"},{"issue":"5","key":"10.1016\/j.bcp.2026.118200_b0010","doi-asserted-by":"crossref","DOI":"10.3390\/biom13050752","article-title":"Update on diabetic kidney disease (DKD): focus on non-albuminuric DKD and cardiovascular risk","volume":"13","author":"Scilletta","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.bcp.2026.118200_b0015","doi-asserted-by":"crossref","unstructured":"S. Mohandes, T. Doke, H. Hu, D. Mukhi, P. Dhillon, K. Susztak, Molecular pathways that drive diabetic kidney disease, J. Clin. Invest. 133(4) (2023). http:\/\/doi.org\/10.1172\/jci165654.","DOI":"10.1172\/JCI165654"},{"key":"#cr-split#-10.1016\/j.bcp.2026.118200_b0020.1","doi-asserted-by":"crossref","unstructured":"S. Rayego-Mateos, R.R. Rodrigues-Diez, B. Fernandez-Fernandez, C. Mora-Fern\u00e1ndez, V. Marchant, J. Donate-Correa, J.F. Navarro-Gonz\u00e1lez, A. Ortiz, M. Ruiz-Ortega, Targeting inflammation to treat diabetic kidney disease: the road to 2030, Kidney Int 103","DOI":"10.1016\/j.kint.2022.10.030"},{"key":"#cr-split#-10.1016\/j.bcp.2026.118200_b0020.2","doi-asserted-by":"crossref","unstructured":"(2) (2023) 282-296.http:\/\/doi.org\/10.1016\/j.kint.2022.10.030.","DOI":"10.1016\/j.kint.2022.10.030"},{"key":"10.1016\/j.bcp.2026.118200_b0025","doi-asserted-by":"crossref","unstructured":"D. Bertheloot, E. Latz, B.S. Franklin, Necroptosis, pyroptosis and apoptosis: an intricate game of cell death, Cell Mol. Immunol. 18(5) (2021) 1106-1121. http:\/\/doi.org\/10.1038\/s41423-020-00630-3.","DOI":"10.1038\/s41423-020-00630-3"},{"issue":"1","key":"10.1016\/j.bcp.2026.118200_b0030","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41392-024-01958-2","article-title":"Pyroptosis in health and disease: mechanisms, regulation and clinical perspective","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"4","key":"10.1016\/j.bcp.2026.118200_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2021.167290","article-title":"Pyroptosis in kidney disease","volume":"434","author":"Wang","year":"2022","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bcp.2026.118200_b0040","doi-asserted-by":"crossref","unstructured":"X. Liu, Z. Zhang, J. Ruan, Y. Pan, V.G. Magupalli, H. Wu, J. Lieberman, Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores, Nature 535(7610) (2016) 153-8. http:\/\/doi.org\/10.1038\/nature18629.","DOI":"10.1038\/nature18629"},{"key":"10.1016\/j.bcp.2026.118200_b0045","doi-asserted-by":"crossref","unstructured":"K. Shahzad, S. Fatima, H. Khawaja, A. Elwakiel, I. Gadi, S. Ambreen, S. Zimmermann, P.R. Mertens, R. Biemann, B. Isermann, Podocyte-specific Nlrp3 inflammasome activation promotes diabetic kidney disease, Kidney Int. 102(4) (2022) 766\u2013779. http:\/\/doi.org\/10.1016\/j.kint.2022.06.010.","DOI":"10.1016\/j.kint.2022.06.010"},{"key":"10.1016\/j.bcp.2026.118200_b0050","article-title":"Astragaloside IV attenuates renal tubule injury in DKD rats via suppression of CD36-mediated NLRP3 inflammasome activation","volume":"15","author":"Li","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118200_b0055","article-title":"Regulation of SIRT1 and its roles in inflammation","volume":"13","author":"Yang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118200_b0060","doi-asserted-by":"crossref","unstructured":"C. Tovar-Palacio, L.G. Noriega, A. Mercado, Potential of polyphenols to restore SIRT1 and NAD+ metabolism in renal disease, Nutrients 14(3) (2022). http:\/\/doi.org\/10.3390\/nu14030653.","DOI":"10.3390\/nu14030653"},{"key":"10.1016\/j.bcp.2026.118200_b0065","doi-asserted-by":"crossref","unstructured":"W.C. Chou, Z. Guo, H. Guo, L. Chen, G. Zhang, K. Liang, L. Xie, X. Tan, S.A. Gibson, E. Rampanelli, Y. Wang, S.A. Montgomery, W.J. Brickey, M. Deng, L. Freeman, S. Zhang, M.A. Su, X. Chen, Y.Y. Wan, J.P. Ting, AIM2 in regulatory T cells restrains autoimmune diseases, Nature 591(7849) (2021) 300\u2013305. http:\/\/doi.org\/10.1038\/s41586-021-03231-w.","DOI":"10.1038\/s41586-021-03231-w"},{"key":"10.1016\/j.bcp.2026.118200_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106533","article-title":"The AIM2 inflammasome: a novel biomarker and target in cardiovascular disease","volume":"186","author":"Du","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2026.118200_b0075","doi-asserted-by":"crossref","unstructured":"T.P. Fidler, C. Xue, M. Yalcinkaya, B. Hardaway, S. Abramowicz, T. Xiao, W. Liu, D.G. Thomas, M.A. Hajebrahimi, J. Pircher, C. Silvestre-Roig, A.G. Kotini, L.L. Luchsinger, Y. Wei, M. Westerterp, H.W. Snoeck, E.P. Papapetrou, C. Schulz, S. Massberg, O. Soehnlein, B. Ebert, R.L. Levine, M.P. Reilly, P. Libby, N. Wang, A.R. Tall, The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis, Nature 592(7853) (2021) 296-301. http:\/\/doi.org\/10.1038\/s41586-021-03341-5.","DOI":"10.1038\/s41586-021-03341-5"},{"issue":"1","key":"10.1016\/j.bcp.2026.118200_b0080","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s11658-022-00402-z","article-title":"Absent in melanoma 2 (AIM2) in rheumatoid arthritis: novel molecular insights and implications","volume":"27","author":"Zhao","year":"2022","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.bcp.2026.118200_b0085","doi-asserted-by":"crossref","unstructured":"L. Lu, R. Shuang, F. Cao, Z. Sun, Q. Wei, T. Gao, X. Gu, K. Wen, X. Cheng, M. Gu, Emodin inhibits AIM2 inflammasome activation via modulating K27-linked polyubiquitination to attenuate renal fibrosis, Phytother. Res. 39(2) (2025) 551\u2013563. http:\/\/doi.org\/10.1002\/ptr.8390.","DOI":"10.1002\/ptr.8390"},{"key":"10.1016\/j.bcp.2026.118200_b0090","doi-asserted-by":"crossref","unstructured":"H. Zou, M. Chen, X. Wang, J. Yu, X. Li, Y. Xie, J. Liu, M. Liu, L. Xu, Q. Zhang, X. Tian, F. Zhang, B. Guo, C\/EBP\u03b2 isoform-specific regulation of podocyte pyroptosis in lupus nephritis-induced renal injury, J. Pathol. 261(3) (2023) 269\u2013285. http:\/\/doi.org\/10.1002\/path.6174.","DOI":"10.1002\/path.6174"},{"key":"10.1016\/j.bcp.2026.118200_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115431","article-title":"Neutrophil extracellular traps mediate macrophage polarization and pyroptosis through the TLR9-NF-\u03baB\/AIM2 pathway exacerbating myositis-associated interstitial lung disease","volume":"165","author":"Cui","year":"2025","journal-title":"Int. Immunopharmacol."},{"issue":"10","key":"10.1016\/j.bcp.2026.118200_b0100","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40265-019-01148-3","article-title":"Dapagliflozin: a review in type 2 diabetes","volume":"79","author":"Dhillon","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.bcp.2026.118200_b0105","doi-asserted-by":"crossref","unstructured":"A.B. Patel, K. Mistry, A. Verma, DAPA-CKD: Significant Victory for CKD with or without Diabetes, Trends Endocrinol Metab 32(6) (2021) 335-337. http:\/\/doi.org\/10.1016\/j.tem.2021.02.007.","DOI":"10.1016\/j.tem.2021.02.007"},{"key":"10.1016\/j.bcp.2026.118200_b0110","doi-asserted-by":"crossref","unstructured":"H.J.L. Heerspink, B.V. Stef\u00e1nsson, R. Correa-Rotter, G.M. Chertow, T. Greene, F.F. Hou, J.F.E. Mann, J.J.V. McMurray, M. Lindberg, P. Rossing, C.D. Sj\u00f6str\u00f6m, R.D. Toto, A.M. Langkilde, D.C. Wheeler, dapagliflozin in patients with chronic kidney disease, N. Engl. J. Med. 383(15) (2020) 1436\u20131446. http:\/\/doi.org\/10.1056\/NEJMoa2024816.","DOI":"10.1056\/NEJMoa2024816"},{"key":"10.1016\/j.bcp.2026.118200_b0115","doi-asserted-by":"crossref","unstructured":"H.J.L. Heerspink, J.F. Cardona, S. Jolly, P.E. Pergola, E. de Sousa-Amorim, A.L. Eriksson, M. Fredholm, S.B. Gasparyan, N.J. Guzman, J. Hartleib-Geschwindner, Y. Jiang, M. Leonsson-Zachrisson, P.B. Mark, Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial, Lancet 406(10518) (2025) 2449\u20132460. http:\/\/doi.org\/10.1016\/s0140-6736(25)02014-8.","DOI":"10.1016\/S0140-6736(25)02014-8"},{"issue":"2","key":"10.1016\/j.bcp.2026.118200_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2025.168074","article-title":"Liu, SIRT1-PINK1-Parkin axis orchestrated mitophagy and renal repair by dapagliflozin in diabetic nephropathy","volume":"1872","author":"Ma","year":"2026","journal-title":"Biochim. Biophys. Acta Mol. basis Dis."},{"key":"10.1016\/j.bcp.2026.118200_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.116857","article-title":"The SGLT2 inhibitor dapagliflozin suppresses endothelial cell pyroptosis mediated by the NF-\u03baB\/NLRP3 pathway through downregulation of CTSB","volume":"236","author":"Zhao","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118200_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2025.123721","article-title":"Comparison of the cardioprotective effects of liraglutide, dapagliflozin and their combination in a rat model of diabetes induced by streptozotocin","volume":"375","author":"Mayyas","year":"2025","journal-title":"Life Sci."},{"key":"10.1016\/j.bcp.2026.118200_b0135","doi-asserted-by":"crossref","unstructured":"T.W.C. Tervaert, A.L. Mooyaart, K. Amann, A.H. Cohen, H.T. Cook, C.B. Drachenberg, F. Ferrario, A.B. Fogo, M. Haas, E. de Heer, K. Joh, L.H. No\u00ebl, J. Radhakrishnan, S.V. Seshan, I.M. Bajema, J.A. Bruijn, o.b.o.t.R.P. Society, Pathologic classification of diabetic nephropathy, J. Am. Soc. Nephrol. 21(4) (2010) 556-563.http:\/\/doi.org\/10.1681\/asn.2010010010.","DOI":"10.1681\/ASN.2010010010"},{"issue":"1","key":"10.1016\/j.bcp.2026.118200_b0140","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s10020-024-01020-5","article-title":"Xu, Targeting programmed cell death in diabetic kidney disease: from molecular mechanisms to pharmacotherapy","volume":"30","author":"Liu","year":"2024","journal-title":"Mol. Med."},{"key":"10.1016\/j.bcp.2026.118200_b0145","article-title":"Targeting programmed cell death pathways: emerging therapeutic strategies for diabetic kidney disease","volume":"16","author":"Wang","year":"2025","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.bcp.2026.118200_b0150","doi-asserted-by":"crossref","unstructured":"S. Zhong, N. Wang, C. Zhang, Podocyte death in diabetic kidney disease: potential molecular mechanisms and therapeutic targets, Int. J. Mol. Sci. 25(16) (2024).http:\/\/doi.org\/10.3390\/ijms25169035.","DOI":"10.3390\/ijms25169035"},{"issue":"6","key":"10.1016\/j.bcp.2026.118200_b0155","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70337","article-title":"Elevation of ISG15 promotes diabetic kidney disease by modulating renal tubular epithelial cell pyroptosis","volume":"15","author":"Huang","year":"2025","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.bcp.2026.118200_b0160","doi-asserted-by":"crossref","unstructured":"A.B. Sanz, M.D. Sanchez-Ni\u00f1o, A.M. Ramos, A. Ortiz, Regulated cell death pathways in kidney disease, Nat. Rev. Nephrol. 19(5) (2023) 281-299. http:\/\/doi.org\/10.1038\/s41581-023-00694-0.","DOI":"10.1038\/s41581-023-00694-0"},{"key":"10.1016\/j.bcp.2026.118200_b0165","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1466440","article-title":"The role of AIM2 in inflammation and tumors","volume":"15","author":"Yu","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118200_b0170","doi-asserted-by":"crossref","unstructured":"R. Chen, J. Duan, Y. Zhou, M. Cao, Y. Su, D. Jiang, A. Tao, W. Yuan, Z. Dai, Endothelial HMGB1-AIM2 axis worsens myocardial ischemia-reperfusion injury by regulating endothelial pyroptosis, Apoptosis 30(9-10) (2025) 2466-2479. http:\/\/doi.org\/10.1007\/s10495-025-02162-5.","DOI":"10.1007\/s10495-025-02162-5"},{"key":"10.1016\/j.bcp.2026.118200_b0175","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1711035","article-title":"Construction and evaluation of STZ-induced diabetes and diabetic kidney disease models in C57BL\/6J mice","volume":"16","author":"Li","year":"2025","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.bcp.2026.118200_b0180","doi-asserted-by":"crossref","unstructured":"L.J. Yan, The nicotinamide\/streptozotocin rodent model of type 2 diabetes: renal pathophysiology and redox imbalance features, Biomolecules 12(9) (2022). http:\/\/doi.org\/10.3390\/biom12091225.","DOI":"10.3390\/biom12091225"},{"key":"10.1016\/j.bcp.2026.118200_b0185","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.biopha.2018.05.130","article-title":"Simvastatin ameliorates diabetic nephropathy by attenuating oxidative stress and apoptosis in a rat model of streptozotocin-induced type 1 diabetes","volume":"105","author":"Al-Rasheed","year":"2018","journal-title":"Biomed. Pharmacother"},{"key":"10.1016\/j.bcp.2026.118200_b0190","doi-asserted-by":"crossref","unstructured":"C.Y. Wang, D.L. Wu, M.H. Yu, C.Y. Wang, H.W. Liang, H.J. Lee, Apple polyphenol mitigates diabetic nephropathy via attenuating renal dysfunction with antioxidation in streptozotocin-induced diabetic rats, Antioxidants (Basel) 14(2) (2025).http:\/\/doi.org\/10.3390\/antiox14020130.","DOI":"10.3390\/antiox14020130"},{"key":"10.1016\/j.bcp.2026.118200_b0195","doi-asserted-by":"crossref","unstructured":"D.C. Wheeler, B.V. Stef\u00e1nsson, N. Jongs, G.M. Chertow, T. Greene, F.F. Hou, J.J.V. McMurray, R. Correa-Rotter, P. Rossing, R.D. Toto, C.D. Sj\u00f6str\u00f6m, A.M. Langkilde, H.J.L. Heerspink, Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial, Lancet Diabetes Endocrinol 9(1) (2021) 22-31.http:\/\/doi.org\/10.1016\/s2213-8587(20)30369-7.","DOI":"10.1016\/S2213-8587(20)30369-7"},{"key":"10.1016\/j.bcp.2026.118200_b0200","doi-asserted-by":"crossref","unstructured":"D.C. Wheeler, R.D. Toto, B.V. Stef\u00e1nsson, N. Jongs, G.M. Chertow, T. Greene, F.F. Hou, J.J.V. McMurray, R. Pecoits-Filho, R. Correa-Rotter, P. Rossing, C.D. Sj\u00f6str\u00f6m, K. Umanath, A.M. Langkilde, H.J.L. Heerspink, A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy, Kidney Int 100(1) (2021) 215-224.http:\/\/doi.org\/10.1016\/j.kint.2021.03.033.","DOI":"10.1016\/j.kint.2021.03.033"},{"key":"10.1016\/j.bcp.2026.118200_b0205","doi-asserted-by":"crossref","unstructured":"N. Jongs, T. Greene, G.M. Chertow, J.J.V. McMurray, A.M. Langkilde, R. Correa-Rotter, P. Rossing, C.D. Sj\u00f6str\u00f6m, B.V. Stefansson, R.D. Toto, D.C. Wheeler, H.J.L. Heerspink, Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial, Lancet Diabetes Endocrinol. 9(11) (2021) 755\u2013766. http:\/\/doi.org\/10.1016\/s2213-8587(21)00243-6.","DOI":"10.1016\/S2213-8587(21)00243-6"},{"key":"10.1016\/j.bcp.2026.118200_b0210","doi-asserted-by":"crossref","unstructured":"V. Martinez Leon, R. Hilburg, K. Susztak, Mechanisms of diabetic kidney disease and established and emerging treatments, Nat. Rev. Endocrinol. 22(1) (2026) 21\u201335. http:\/\/doi.org\/10.1038\/s41574-025-01171-3.","DOI":"10.1038\/s41574-025-01171-3"},{"key":"10.1016\/j.bcp.2026.118200_b0215","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.freeradbiomed.2022.12.088","article-title":"Empagliflozin attenuates the renal tubular ferroptosis in diabetic kidney disease through AMPK\/NRF2 pathway","volume":"195","author":"Lu","year":"2023","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.bcp.2026.118200_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2022.102260","article-title":"Upregulation of TIPE1 in tubular epithelial cell aggravates diabetic nephropathy by disrupting PHB2 mediated mitophagy","volume":"50","author":"Liu","year":"2022","journal-title":"Redox Biol."},{"key":"10.1016\/j.bcp.2026.118200_b0225","doi-asserted-by":"crossref","unstructured":"X.C. Zhao, L. Zhang, H.X. Yu, Z. Sun, X.F. Lin, C. Tan, R.R. Lu, Curcumin protects mouse neuroblastoma Neuro-2A cells against hydrogen-peroxide-induced oxidative stress, Food Chem. 129(2) (2011) 387\u2013394. http:\/\/doi.org\/10.1016\/j.foodchem.2011.04.089.","DOI":"10.1016\/j.foodchem.2011.04.089"},{"key":"10.1016\/j.bcp.2026.118200_b0230","doi-asserted-by":"crossref","unstructured":"J. Xu, M. Kitada, Y. Ogura, H. Liu, D. Koya, Dapagliflozin restores impaired autophagy and suppresses inflammation in high glucose-treated HK-2 cells, Cells 10(6) (2021).http:\/\/doi.org\/10.3390\/cells10061457.","DOI":"10.3390\/cells10061457"},{"issue":"8","key":"10.1016\/j.bcp.2026.118200_b0235","article-title":"The SGLT2 inhibitor dapagliflozin ameliorates renal fibrosis in hyperuricemic nephropathy","volume":"5","author":"Hu","year":"2024","journal-title":"Cell Rep. Med."},{"issue":"3","key":"10.1016\/j.bcp.2026.118200_b0240","doi-asserted-by":"crossref","first-page":"27082","DOI":"10.31083\/FBL27082","article-title":"Dapagliflozin attenuates myocardial inflammation and apoptosis after coronary microembolization in rats by regulating the SIRT1\/NF-\u03baB signaling pathway","volume":"30","author":"Li","year":"2025","journal-title":"Front. Biosci. (Landmark Ed)"},{"issue":"15","key":"10.1016\/j.bcp.2026.118200_b0245","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25158541","article-title":"The beneficial effect of the SGLT2 inhibitor dapagliflozin in alleviating acute myocardial infarction-induced cardiomyocyte injury by increasing the sirtuin family SIRT1\/SIRT3 and cascade signaling","volume":"25","author":"Lin","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.118200_b0250","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1186\/s12933-023-02040-x","article-title":"SIRT1 mediates the inhibitory effect of Dapagliflozin on EndMT by inhibiting the acetylation of endothelium Notch1","volume":"22","author":"Wang","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.bcp.2026.118200_b0255","doi-asserted-by":"crossref","unstructured":"A.M. Davenport, F.M. Huber, A. Hoelz, Structural and functional analysis of human SIRT1, J. Mol. Biol. 426(3) (2014) 526\u201341. http:\/\/doi.org\/10.1016\/j.jmb.2013.10.009.","DOI":"10.1016\/j.jmb.2013.10.009"},{"key":"10.1016\/j.bcp.2026.118200_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115125","article-title":"Dapagliflozin attenuates myocardial hypertrophy via activating the SIRT1\/HIF-1\u03b1 signaling pathway","volume":"165","author":"Yang","year":"2023","journal-title":"Biomed. Pharmacother"},{"key":"10.1016\/j.bcp.2026.118200_b0265","doi-asserted-by":"crossref","unstructured":"N. Schmid, K.G. Dietrich, I. Forne, A. Burges, M. Szymanska, R. Meidan, D. Mayr, A. Mayerhofer, Sirtuin 1 and sirtuin 3 in granulosa cell tumors, Int. J. Mol. Sci. 22(4) (2021). http:\/\/doi.org\/10.3390\/ijms22042047.","DOI":"10.3390\/ijms22042047"},{"issue":"1","key":"10.1016\/j.bcp.2026.118200_b0270","first-page":"23","article-title":"Down-regulation of Risa improves podocyte injury by enhancing autophagy in diabetic nephropathy","volume":"9","author":"Su","year":"2022","journal-title":"Mil. Med. Res."},{"key":"10.1016\/j.bcp.2026.118200_b0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.mad.2022.111724","article-title":"The SIRT1 activator SRT2104 promotes BMP9-induced osteogenic and angiogenic differentiation in mesenchymal stem cells","volume":"207","author":"Lu","year":"2022","journal-title":"Mech. Ageing Dev."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226005393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226005393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T13:14:13Z","timestamp":1785071653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226005393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":56,"alternative-id":["S0006295226005393"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118200","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dapagliflozin ameliorates diabetic kidney disease by inhibiting oxidative stress and AIM2-dependent pyroptosis via SIRT1 activation","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118200","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118200"}}